CBS 2019
CBSMD教育中心
中 文

科学研究

Abstract

Recommended Article

From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5) Timing of intervention in asymptomatic patients with valvular heart disease Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus Myofibroblast Phenotype and Reversibility of Fibrosis in Patients With End-Stage Heart Failure Prevalence and clinical implications of valvular calcification on coronary computed tomography angiography Optical Frequency Domain Imaging Versus Intravascular Ultrasound in Percutaneous Coronary Intervention (OPINION Trial) Results From the OPINION Imaging Study DAPT, Our Genome and Clopidogrel

Editorial2017 Oct 1;2(10):1061-1062.

JOURNAL:JAMA Cardiol. Article Link

What Is the Optimal Revascularization Strategy for Left Main Coronary Stenosis?

Ruel M, Verma S, Bhatt DL. Keywords: PCI; CABG; repeat revascularization

ABSTRACT

Over the last months, 2 major trials and several meta-analyses have been published on the treatment of stable, unprotected left main coronary artery stenosis. Currently, North American and European guidelines for the treatment of left main stenosis indicate a class I recommendation for the performance of coronary artery bypass grafting (CABG). They also indicate a class IIa to III (North American) or a class I to III (European) recommendation for percutaneous coronary intervention (PCI), depending on the complexity of the coronary anatomy as determined by the Synergy Between PCI With Taxus and Cardiac Surgery (SYNTAX) score.